Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYSA-5: KYV 101 in Systemic Sclerosis
NCT06400303Phase 2Terminated
- Sponsor
- Kyverna Therapeutics
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of mivocabtagene autoleucel in systemic sclerosis (SSc) (2 arms), sponsored by Kyverna Therapeutics. Primary endpoints: Incidence of adverse events and laboratory abnormalities up to 2 years, Frequency of Dose-Limiting Toxicities up to 2 years and 1 more. Started Aug 2024; status: terminated.
02
Drugs
mivocabtagene autoleucel
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06400303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400303.